ImmunoGen, Inc. IMGN announces its next round of earnings Friday. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement.
Earnings and Revenue
Analysts are predicting ImmunoGen will report a loss of 31 cents per share on revenue of $13.84 million.
In the same quarter last year, ImmunoGen reported a loss per share of 37 cents on revenue of $8.48 million. Sales would be have grown 63.21 percent from the same quarter last year. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
| Quarter | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 |
| EPS Estimate | -0.29 | -0.24 | -0.1 | -0.2 |
| EPS Actual | -0.31 | -0.3 | -0.11 | -0.37 |
Stock Performance
Over the last 52-week period, shares are down 5.89 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.
Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with ImmunoGen. The strength of this rating has maintained conviction over the past three months.
Conference Call
ImmunoGen's Q3 is scheduled to hold a conference call at 8:00 a.m. ET and it can be accessed here: https://edge.media-server.com/m6/p/bm3anrda
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
